Skip to content
WELCOME10 — 10% OFF YOUR FIRST ORDER  ·  FREE SHIPPING OVER $300 CAD  ·  COA ON EVERY ORDER
Research Comparison

CJC-1295 (No DAC) vs Tirzepatide

CJC-1295 (No DAC) and Tirzepatide are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.

Shared research areas:Metabolic
ClassGHRH(1-29) tetra-substituted analogue (DAC-free)Lipidated dual receptor agonist (GIP / GLP-1), 39-residue chain
Molecular weight3367.9 g/mol4813.5 g/mol
CAS numberNot assigned / not specifiedNot assigned / not specified
Purity spec≥99%≥99%
Research areasHormonal & Endocrine, MetabolicMetabolic
Primary diluentBacteriostatic water (0.9% benzyl alcohol)Bacteriostatic water (0.9% benzyl alcohol)
Working windowCommonly worked with for 2-3 weeks at 2-8 °C.Commonly worked with for 4–6 weeks at 2–8 °C.
Lead degradation routeDeamidation at Asn/Gln residues over long solution storage.Interfacial aggregation from agitation or freezing — the dominant practical route.
Freeze–thawAliquot on first reconstitution; avoid re-freezing the solution.Do not freeze reconstituted solution. Interfacial aggregation during freezing is the characteristic failure mode and is irreversible.
Light sensitivityNo specific light requirement beyond normal practice.No specific light requirement beyond normal practice.

How they actually differ

Comparing the two: CJC-1295 (No DAC) is ghrh(1-29) tetra-substituted analogue (dac-free), while Tirzepatide is lipidated dual receptor agonist (gip / glp-1), 39-residue chain — different molecular classes with different handling consequences; their leading degradation routes differ (deamidation at asn/gln residues over long solution storage. for CJC-1295 (No DAC), interfacial aggregation from agitation or freezing for Tirzepatide), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.

CJC-1295 (No DAC) — origin

CJC-1295 without DAC is the first 29 residues of growth-hormone-releasing hormone carrying four stabilising substitutions (D-Ala2, Gln8, Ala15, Leu27) that resist DPP-4 cleavage. Omitting the Drug Affinity Complex — the albumin-binding element of the DAC version — gives it a short half-life, which is the property researchers study it for.

Tirzepatide — origin

Tirzepatide is built on a GIP-based backbone rather than a GLP-1 one — an important and often-missed design detail. It was engineered from the GIP sequence and modified to acquire GLP-1 receptor activity, with a C20 fatty diacid attached via a linker for albumin binding. The term "twincretin" describes the dual incretin activity.

CJC-1295 (No DAC) research themes

Pulsatile GH release

Studied for prompting growth-hormone release in short, physiological pulses via the GHRH receptor.

DPP-4 resistance

The four substitutions are studied for extending the molecule beyond the minutes-long survival of native GHRH.

Complementary pairing

Frequently studied alongside ghrelin-receptor secretagogues such as Ipamorelin, which recruit a second GH-release pathway.

Tirzepatide research themes

Dual incretin engagement

Simultaneous GIP and GLP-1 receptor activity from a GIP-derived backbone.

Insulin secretion and glucagon suppression

Core metabolic research endpoints for the incretin class.

Gastric emptying

A well-characterised GLP-1 pathway effect studied in metabolic models.

GIP receptor pharmacology

Whether GIP agonism or antagonism is the productive direction remains an active research debate.

CJC-1295 (No DAC) handling

  • Reach room temperature before opening.
  • Swirl to dissolve; do not shake or vortex — foam indicates interfacial stress on the helix.
  • Aliquot and refrigerate; never re-freeze reconstituted solution.

Tirzepatide handling

  • Swirl, never shake or vortex.
  • Add diluent down the vial wall and give the cake time — several minutes of slow dissolution is normal, not a defect.
  • Store upright and refrigerated; do not freeze once reconstituted.

Both third-party tested

Every Popular Peptides batch of CJC-1295 (No DAC) and Tirzepatide is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.

Verify a batchPublished COAsHow we test

CJC-1295 (No DAC) reference

Full CJC-1295 (No DAC) reference CJC-1295 (No DAC) storage CJC-1295 (No DAC) reconstitution CJC-1295 (No DAC) calculatorCJC-1295 (No DAC) product details

Tirzepatide reference

Full Tirzepatide reference Tirzepatide storage Tirzepatide reconstitution Tirzepatide calculatorTirzepatide product details

Related comparisons

5-Amino-1MQ vs CJC-1295 (No DAC)5-Amino-1MQ vs TirzepatideCJC-1295 (No DAC) vs CJC-1295 + IpamorelinCJC-1295 (No DAC) vs IGF-1CJC-1295 (No DAC) vs IGF-1 LR3CJC-1295 (No DAC) vs IpamorelinCJC-1295 (No DAC) vs KisspeptinCJC-1295 (No DAC) vs MOTS-C

CJC-1295 (No DAC) and Tirzepatide are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.